Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

被引：0
|
作者：
Zhifei Li [1 ]
Huan Zhao [2 ]
Huihui Hu [1 ]
Haili Shang [1 ]
Yongjing Ren [1 ]
Wenhui Qiu [3 ]
Hao Su [4 ]
Huifang Lyu [5 ]
Xiaobing Chen [1 ]
机构：
[1] Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital, Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Canc
[2] Henan University of Traditional Chinese Medicine
[3] State Key Laboratory of Esophageal Cancer Prevention&Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences,Zhengzhou University
[4] The First Affiliated Hospital of Xinxiang Medical University
[5] Department of Oncology, the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer
来源：
Chinese Journal of Cancer Research | 2024年 / 36卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R735.2 [胃肿瘤];
学科分类号：
摘要：
Gastric cancer is one of the most prevalent cancers worldwide, and human epidermal growth factor receptor 2(HER2)-positive cases account for approximately 20% of the total cases. Currently, trastuzumab + chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer, and the combination has exhibited definite efficacy in HER2-targeted therapy. However, the emergence of drug resistance during treatment considerably reduces its effectiveness; thus, it is imperative to investigate the potential mechanisms underlying resistance. In the present review article, we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases, aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.
引用
收藏
页码：306 / 321
页数：16
相关论文
共 50 条
  • [31] Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
    Sonnenblick, Amir
    Salmon-Divon, Mali
    Salgado, Roberto
    Ponde, Noam
    Loibl, Sibylle
    Denkert, Carsten
    Joensuu, Heikki
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Azaria, Amos
    Loi, Sherene
    Michiels, Stefan
    Sotiriou, Christos
    CANCER RESEARCH, 2020, 80 (04)
  • [32] Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
    Sonnenblick, Amir
    Salmon-Divon, Mali
    Salgado, Roberto
    Dvash, Efrat
    Ponde, Noam
    Zahavi, Tamar
    Salmon, Asher
    Loibl, Sibylle
    Denkert, Carsten
    Joensuu, Heikki
    Ameye, Lieveke
    Van den Eynden, Gert
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Azaria, Amos
    Loi, Sherene
    Michiels, Stefan
    Richard, Francois
    Sotiriou, Christos
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 266 - 276
  • [33] HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch
    Dubianski, R.
    Sarnowska, E.
    Leszczynski, M.
    Kubala, S.
    Olszewski, W.
    Rusetska, N.
    Jagiello-Gruszfeld, A. I.
    Konopinski, R.
    Sarnowski, T. J.
    Siedlecki, J. A.
    Nowecki, Z. I.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Trastuzumab in HER2-Positive Metastatic Gastric CancerProfile Report
    Jamie D. Croxtall
    Kate McKeage
    BioDrugs, 2011, 25 : 257 - 259
  • [35] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Hori, Ami
    Shimoda, Masafumi
    Naoi, Yasuto
    Kagara, Naofumi
    Tanei, Tomonori
    Miyake, Tomohiro
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [36] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Ami Hori
    Masafumi Shimoda
    Yasuto Naoi
    Naofumi Kagara
    Tomonori Tanei
    Tomohiro Miyake
    Kenzo Shimazu
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research, 21
  • [37] Trastuzumab biosimilar for HER2-positive breast and gastric carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 482 - 483
  • [38] Dissecting the molecular mechanisms underlying therapy resistance and sensitivity in HER2-positive gastric cancer
    Fernandes Neto, Joao M.
    Mesquita, Barbara
    Pereira, Carla
    Martins, Diana
    Carvalho, Joana
    Leitao, Dina
    Ferreira, Marta
    Ferreira, Pedro
    Carneiro, Fatima
    Almeida, Gabriela M.
    Oliveira, Carla
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 729 - 730
  • [39] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [40] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
12345